WebInotuzumab ozogamicin is the generic name for the trade name drug Besponsa® when referring to the generic drug name inotuzumab ozogamicin. Drug Type: Inotuzumab … WebIs BESPONSA chemotherapy? It contains inotuzumab, an antibody that's linked to ozogamicin, a chemotherapy drug. So Besponsa is both a targeted therapy and a chemotherapy drug. Inotuzumab is designed to find and attach to a specific target, a protein called CD22. This protein is found on leukemia cells and healthy B cells.
Efficacy and safety of concomitant chemo-endocrine therapy in ...
WebBESPONSA- inotuzumab ozogamicin injection, powder, lyophilized, for solution Wyeth ... -HSCT non-relapse mortality rate was observed in patients receiving BESPONSA compared to the Investigator's choice of chemotherapy arm, resulting in a higher Day 100 post-HSCT mortality rate. Overall, 79/164 patients (48%) in the BESPONSA arm and ... Web22 jul. 2024 · Relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) has a poor prognosis. 1 Results from the SCHOLAR-1 and Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) studies suggest that response rates to available rituximab-based salvage regimens for r/r DLBCL remain dismal and are unlikely to be durable. 1-3 In … blank creations
Besponsa® Pfizer
WebThe efficacy of BESPONSA was established on the basis of CR, duration of CR, and proportion of MRD-negative CR (<1 x 10-4 of bone marrow nucleated cells by flow … Web1 mei 2008 · Complete Remission Rate: Percentage of Participants With Complete Remission (CR) [ Time Frame: After two 21-day courses, response to treatment checked for Complete Remission (CR) ] Complete Remission (CR) was defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count ≥1.0 × 10^9/L, a platelet … Web17 sep. 2024 · Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL). Besponsa is used on its own in adults whose cancer has come back or … The pages listed below are relevant for sponsors of medicines that have … P/0062/2024: EMA decision of 10 February 2024 on the acceptance of a … Early development advice services. EMA has developed a consolidated list of … Summary of Product Characteristics - Besponsa European Medicines Agency Careers - Besponsa European Medicines Agency Package Leaflet - Besponsa European Medicines Agency Using connector words, quotation marks and truncation in the keyword search … francebased cegid spanish smbstimes